Abstract: Disclosed are an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. An electrolyte solution for a lithium secondary battery includes a lithium salt, a solvent, and a functional additive, and in particular, the functional additive includes (4-(1H-1,2,4-triazol-1-yl)phenyl)(fluorosulfonyl)sulfamoyl fluoride.

Abstract: The present disclosure relates to an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. An electrolyte solution for a lithium secondary battery includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes a first electrode film additive, which is 3-(4-cyano-5-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl 4-methylbenzenesulfonate.

Abstract: Disclosed are an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. The electrolyte solution includes a lithium salt, a solvent, and a functional additive. The functional additive includes benzo[d]thiazol-6-yl(fluorosulfonyl)sulfamoyl fluoride.

Abstract: The present disclosure relates to an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. An electrolyte solution for a lithium secondary battery includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes a positive-electrode film additive, which is 3-(4-cyano-5-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl methanesulfonate.

Abstract: Provided is a cluster node recommendation system. A method of controlling the cluster node recommendation system includes: inputting user selection information from a user, the user selection information including at least one of a cloud vendor, an Information Technology (IT) resource size, and a free resource size; checking resource requirements of a designated application; outputting a node configuration by inputting the input user selection information and the checked resource requirements of the application to an artificial intelligence module; verifying validity by arranging a container in which the application is executed, in the output node configuration; and providing a final node configuration in which validity verification is made, to the user.

Abstract: The present invention relates to a composition for preventing or treating asthma comprising a Pistacia weinmannifolia J. Poiss. ex Franch extract or a fraction thereof. The Pistacia weinmannifolia J. Poiss. ex Franch extract or the fraction thereof according to the present invention does not exhibit toxicity, inhibits the generation of NO, IL-4, IL-5, and IL-13 and the generation of reactive oxygen species in the bronchial tubes, and has significantly induced the alleviation of airway hyperresponsiveness, inhibition of the infiltration of inflammatory cells into the bronchial tubes, and reduction of inflammatory cells in bronchoalveolar lavage fluid in an ovalbumin-induced asthma mouse model. In addition, the Pistacia weinmannifolia J. Poiss.

Abstract: A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-? and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract: A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-? and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Abstract: A method and apparatus for energy adaptive resource allocation in energy harvesting network are provided. The method includes: allocating, by an energy adaptive resource allocation apparatus, non-competition slots of a next frame to at least one first wireless communication device whose energy queue state exceeds a predetermined threshold value among wireless communication devices succeeded in data transmission; and allocating, by the energy adaptive resource allocation apparatus, competition slots of the same number as that of at least one third wireless communication device expected to attempt data transmission to the next frame in consideration of a harvested energy amount and an average energy harvesting rate of at least one second wireless communication device.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract: A method and apparatus for energy adaptive resource allocation in energy harvesting network are provided. The method includes: allocating, by an energy adaptive resource allocation apparatus, non-competition slots of a next frame to at least one first wireless communication device whose energy queue state exceeds a predetermined threshold value among wireless communication devices succeeded in data transmission; and allocating, by the energy adaptive resource allocation apparatus, competition slots of the same number as that of at least one third wireless communication device expected to attempt data transmission to the next frame in consideration of a harvested energy amount and an average energy harvesting rate of at least one second wireless communication device.

Abstract: The present invention relates to a composition for preventing or treating asthma comprising a Pistacia weinmannifolia J. Poiss. ex Franch extract or a fraction thereof. The Pistacia weinmannifolia J. Poiss. ex Franch extract or the fraction thereof according to the present invention does not exhibit toxicity, inhibits the generation of NO, IL-4, IL-5, and IL-13 and the generation of reactive oxygen species in the bronchial tubes, and has significantly induced the alleviation of airway hyperresponsiveness, inhibition of the infiltration of inflammatory cells into the bronchial tubes, and reduction of inflammatory cells in bronchoalveolar lavage fluid in an ovalbumin-induced asthma mouse model. In addition, the Pistacia weinmannifolia J. Poiss.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases or asthma comprising a Lagerstroemia ovalifolia extract or a fraction thereof as an active ingredient, and a health functional food and a feed additive for preventing or improving inflammatory diseases or asthma comprising the extract or the fraction as an active ingredient.

Abstract: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to an antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient. In detail, extracts of Aleurites fordii or Daphne kiusiana or fractions thereof can induce the secretion of an immune-related cytokine, interferon-? (IFN-?) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).